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Background: Steroidogenic acute regulatory protein (StAR)-related lipid transfer (START) domains were first
identified from mammalian proteins that bind lipid/sterol ligands via a hydrophobic pocket. In plants, predicted
START domains are predominantly found in homeodomain leucine zipper (HD-Zip) transcription factors that are
master regulators of cell-type differentiation in development. Here we utilized studies of Arabidopsis in parallel with
heterologous expression of START domains in yeast to investigate the hypothesis that START domains are versatile
ligand-binding motifs that can modulate transcription factor activity.
Results: Our results show that deletion of the START domain from Arabidopsis Glabra2 (GL2), a representative
HD-Zip transcription factor involved in differentiation of the epidermis, results in a complete loss-of-function
phenotype, although the protein is correctly localized to the nucleus. Despite low sequence similarly, the mammalian
START domain from StAR can functionally replace the HD-Zip-derived START domain. Embedding the START domain
within a synthetic transcription factor in yeast, we found that several mammalian START domains from StAR, MLN64
and PCTP stimulated transcription factor activity, as did START domains from two Arabidopsis HD-Zip transcription
factors. Mutation of ligand-binding residues within StAR START reduced this activity, consistent with the yeast assay
monitoring ligand-binding. The D182L missense mutation in StAR START was shown to affect GL2 transcription factor
activity in maintenance of the leaf trichome cell fate. Analysis of in vivo protein–metabolite interactions by mass
spectrometry provided direct evidence for analogous lipid-binding activity in mammalian and plant START domains in
the yeast system. Structural modeling predicted similar sized ligand-binding cavities of a subset of plant START domains
in comparison to mammalian counterparts.
Conclusions: The START domain is required for transcription factor activity in HD-Zip proteins from plants, although
it is not strictly necessary for the protein’s nuclear localization. START domains from both mammals and plants are
modular in that they can bind lipid ligands to regulate transcription factor function in a yeast system. The data provide
evidence for an evolutionarily conserved mechanism by which lipid metabolites can orchestrate transcription. We
propose a model in which the START domain is used by both plants and mammals to regulate transcription factor
activity.
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Steroidogenic acute regulatory protein (StAR)-related lipid
transfer (START) is an evolutionarily conserved module
of approximately 200 amino acids implicated in lipid/
sterol binding [1]. The prototype for the START domain
is found in mammalian StAR proteins that bind choles-
terol for the initiation of steroidogenesis [2]. The START
domain subfamily belongs to an expansive clan of α/β
helix-grip-fold structures that is given the name ‘SRPBCC
(START/RHO_alpha_C/PITP/Bet_v1/CoxG/CalC) super-
family’ in the NCBI Conserved Domains Database, named
for six of its major subfamilies. Another subfamily termed
PYR/PYL/RCAR-like includes the newly identified absci-
sic acid receptors from plants [3,4]. Members of the
SRPBCC superfamily, also referred to in the literature as
the Bet_v1-like [5] or START [6] superfamily, exhibit the
common property of a deep hydrophobic ligand-binding
pocket. The focus of the present study is on proteins carrying
domains of the START subfamily, and we restrict the term
‘START’ to the subfamily of proteins that share significant
sequence similarity to mammalian StAR, as described in [7].
START domains vary in size and configuration and occur
primarily in animals and plants as well as some species from
other taxa. While the StAR protein contains the START do-
main as the major motif, START domains are modular in
that they are found in combination with other functional do-
mains. Ligand-binding by the START domain in a multido-
main protein may regulate the activities of other domains
such as Rho-GAP and thioesterase domains that occur in
human START domain-containing proteins.
Experimental evidence for START domains as ligand-
binding motifs derives largely from mammalian proteins
[8,9]. The human genome encodes 15 START domain-
containing proteins, several of which are implicated in
disease [10]. Human StAR/STARD1 is associated with
an inherited disorder known as congenital lipoid adrenal
hyperplasia (CAH) [11]. Identified ligands for mamma-
lian proteins include sterols such as cholesterol and
hydroxycholesterol, and other lipids such as phospholipids
and sphingolipids. More recently bile acids were shown to
bind human STARD5 [12], expanding the repertoire of
possible interactors. Mammalian START domain crystal
structures are available, revealing central antiparallel β-
sheets and a carboxy-terminal α-helix forming a hydropho-
bic cavity to accommodate a single ligand [13-17]. Ligand
specificity is thought to be conferred by the configuration
of amino acids that form the inner lining of the cavity.
Amino acid changes that perturb START domain func-
tion were uncovered in defective StAR genes from CAH
patients, and specific amino acids are predicted to affect
cholesterol binding [16]. The co-crystal of phosphat-
idylcholine transfer protein (PCTP)/STARD2 bound to
phosphatidylcholine (PtCho) identified multiple residues
that contact the ligand in the hydrophobic pocket [14].The structures of CERT/STARD11 in its apo-form and in
complex with ceramides of variable acyl chain lengths in-
dicate contact points between amino acids and molecular
features of sphingolipids [17].
START domain-containing proteins are abundant in the
plant kingdom, where the majority are members of a plant-
specific homeodomain leucine zipper (HD-Zip) transcrip-
tion factor family [7]. Arabidopsis contains 21 HD-Zip
START domain-containing transcription factors of the class
III and IV subfamilies. Genetic analysis indicates key roles
in cell differentiation and patterning in development, and
several family members exhibit striking mutant phenotypes.
The class III HD-Zip family contains five proteins impli-
cated in vasculature, meristem initiation and/or organ po-
larity [18]. The larger class IV HD-Zip family comprises 16
members involved in cell fate determination [19], and in-
cludes Arabidopsis Meristem Layer 1 (ATML1) and its close
relative Protodermal Factor 2 (PDF2), which are required
for epidermal cell fate of the shoot [20,21], and Glabra2
(GL2), which is required for the specification of epidermal
cells in the shoot [22], root [23] and seed [24].
Although START domains are amplified in HD-Zip tran-
scription factors, the function of the plant domains in lipid/
sterol binding has not been verified, nor has the crystal
structure been solved for any plant-derived START-
subfamily domain to date. Since HD-Zip proteins are tran-
scription factors, one hypothesis is that the START domain,
by binding lipid/sterol ligands, controls transcription analo-
gously to steroid hormone receptors in metazoans [1,7].
One advantage of the proposed mechanism is that the
metabolic state of a cell as reflected in lipid/sterol synthe-
sis could dictate cell-type specific mRNA expression. Such
a mechanism would be of broad interest since many or-
ganisms contain START domain proteins whose functions
have not yet been uncovered.
In this study, the overall aim was to investigate the role of
the START domain in transcription. We demonstrate that
the START domain is required for transcription factor ac-
tivity of a representative HD-Zip protein, GL2, in Arabidop-
sis. A domain swap experiment indicated that although
START domains in mammals and plants exhibit marginal
sequence similarity, their function appears to be conserved.
We utilized a yeast system to assess the roles of START do-
mains in the context of transcription, and to compare the
behavior of known ligand-binding START domains from
mammals to ‘orphan’ START domains from plants. With
this approach, ligand-binding activity for several mamma-
lian domains with known ligands was reproduced in yeast.
START domains from both plants and mammals were
shown to stimulate transcription factor activity when placed
in a yeast synthetic transcription factor. Immunoisolation
of the synthetic transcription factors followed by mass spec-
trometry indicated that START domains from two HD-Zip
transcription factors participate in protein–metabolite
Figure 1 Function of the START domain in HD-Zip transcription factor GL2 from Arabidopsis. (A) Rosettes exhibiting leaf trichomes in
wild-type (WT), and reduction of trichomes in the gl2 null mutant. Scale bar: 2 mm. (B) Roots were germinated on 0.8% agar medium and imaged after
3 to 5 days. gl2 mutant exhibits excessive root hairs in comparison to WT. Scale bar: 200 μm. (C) Mucilage of WT seeds was stained with ruthenium
red after imbibition. gl2 mutants lack mucilage layer. Scale bar: 20 μm. (A, B, C) EYFP:GL2 displays complete rescue of the mutant phenotype while EYFP:
GL2-StAR-START (pink) and EYFP:GL2-ATML1-START exhibit partial rescue. The phenotypes of EYFP:gl2ΔSTART, EYFP:GL2-EDR2-START and EYFP:GL2-REV-START
are indistinguishable from gl2. (D) Schematic diagrams of the EYFP:GL2 and EYFP:gl2ΔSTART proteins depicting enhanced yellow fluorescence protein
(EYFP), homeodomain (HD), Zip-Loop-Zipper (ZLZ) and START-adjacent domain (SAD). For specific constructs, the START domain was deleted or replaced
with a heterologous START domain. (E) Trichomes were counted on the first leaves of 1-week-old plants grown on soil. Error bars indicate standard
deviations for n= 20. (F) Amino acid similarities and identities of Arabidopsis ATML1, REV and EDR2 START domains (green) and mouse StAR START
domain (pink) in comparison to the Arabidopsis GL2 START domain. Amino acid sizes of corresponding START domains are indicated in parentheses. aa,
amino acid; ATML1, Arabidopsis thaliana Meristem Layer 1; EDR2, Enhanced Disease Resistance 2; EYFP, enhanced yellow fluorescent protein; GL2, Glabra2; HD,
homeodomain; REV, Revoluta; SAD, START adjacent domain; StAR, steroidogenic acute regulatory protein; START, StAR-related lipid transfer; WT, wild type.
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vide experimental evidence for a model in which ligand-
binding to the START domain regulates transcription fac-
tor activity, linking metabolism to gene expression.
Results
Deletion of the START domain from HD-Zip transcription
factor GL2 results in loss of activity
To probe the function of the START domain within
HD-Zip transcription factors we chose Arabidopsis GL2Figure 2 Nuclear localization of HD-Zip transcription factor GL2. Conf
wild-type EYFP:GL2 and (B) EYFP:gl2ΔSTART proteins, indicating nuclear loc
(blue), EYFP (yellow) and merge (green) display nuclear localization of EYFP
trichomes indicates nuclear localization of (D) EYFP:GL2 and (E) EYFP:gl2ΔS
the (F) mouse StAR (pink) or (G) ATML1 START domains. Domain swaps wi
in trichomes. Light (left; green, chlorophyll) and matching fluorescence (rig
100 μm. ATML1, Arabidopsis thaliana Meristem Layer 1; DAPI, 4′,6-diamidino
enhanced yellow fluorescent protein; GL2, Glabra2; REV, Revoluta; StAR, ste
YFP, yellow fluorescent protein.for analysis. The GL2 gene product is dispensable for via-
bility, but gl2 null mutants exhibit distinct phenotypes in
differentiation of the epidermis, including defects in leaf
trichome development [22] (Figure 1A; Additional file 1:
Figure S1A), excessive root hair formation [23] (Figure 1B)
and lack of seed mucilage production [24] (Figure 1C).
We deleted the START domain from a GL2 construct in
which the cDNA sequence was translationally fused to the
enhanced yellow fluorescent protein (EYFP) tag at its
amino-terminus (Figure 1D), and transformed gl2 plantsocal laser scanning images show Arabidopsis ovules expressing (A)
alization in immature mucilage secretory cells. (C) Nuclear stain DAPI
:gl2ΔSTART from (B). (A, B, C) Scale bar: 20 μm. Live imaging of leaf
TART, as well as EYFP:GL2-START domain swap proteins containing
th (H) EDR2 or (I) REV START domains result in diffuse expression
ht; red, chlorophyll) images are shown for each construct. Scale bar:
-2-phenylindole; EDR2, Enhanced Disease Resistance 2; EYFP,
roidogenic acute regulatory protein; START, StAR-related lipid transfer;
Schrick et al. BMC Biology 2014, 12:70 Page 5 of 20
http://www.biomedcentral.com/1741-7007/12/70to examine complementation of the mutant phenotypes.
The EYFP:GL2 transgene was expressed under the native
GL2 promoter (ProGL2). Whereas the wild-type ProGL2:
EYFP:GL2 construct rescued all three mutant pheno-
types regarding leaves, roots and seeds, the ProGL2:
EYFP:gl2ΔSTART construct resulted in null phenotypes in-
distinguishable from the gl2 loss-of-function mutant
(Figure 1A,B,C,E). Despite the inability of the EYFP:
gl2ΔSTART transgene to confer phenotypic complementa-
tion, we observed nuclear localization in ovules and
trichomes, similar to that for the wild-type EYFP:GL2
transgene (Figure 2A–E).
The START domain from mouse StAR functionally
replaces the endogenous START domain from GL2
The 209 amino acid START domain from the mouse
StAR domain shares 33% similarity and 13% identity with
the 235 amino acid START domain from Arabidopsis GL2
(Figure 1F). We used a domain swap experiment to test
the ability of this mammalian StAR START domain to re-
place the Arabidopsis START domain functionally in the
EYFP:GL2 protein cassette (Figure 1D). Among the T2
transformants of gl2, we characterized several independ-
ent lines that exhibited partial rescue of the trichome de-
fects and selected one of these lines for detailed analysis.
In addition to partial complementation of the trichome
defects (Figure 1A,E and Additional file 1: Figure S1), these
lines also exhibited partial rescue of the root hair pattern-
ing (Figure 1B) and seed mucilage defects (Figure 1C) of
gl2 null mutants. The results indicate that despite relatively
low sequence similarity (33%), a mammalian START do-
main is able to replace the plant START domain from GL2
functionally to a similar level as that of a related class IV
HD-Zip family member, ATML1 [21] (Figure 1A–E and
Additional file 1: Figure S1). START domain swaps with
mouse StAR or Arabidopsis ATML1 both resulted in nu-
clear localization of the EYFP:GL2 protein (Figure 2F,G).
The function of the START domain in GL2 was dependent
on the encoded domain sequence, since replacement
with two additional Arabidopsis-derived START domains,
namely from Enhanced Disease Resistance 2 (EDR2)
[25] and from class III HD-Zip member Revoluta (REV)
[26], were not found to rescue the gl2 mutant pheno-
type (Figure 1A,B,C,E), nor did they display nuclear
localization (Figure 2H,I).
A yeast assay for START domain function in transcription
We developed an assay to monitor the activity of the
START domain within a synthetic transcription factor
using heterologous expression in the yeast Saccharomyces
cerevisiae. The START domain-coding region from various
proteins (Figure 3A) was fused between an amino-
terminal GAL4 DNA binding domain (DBD) and a
carboxy-terminal VP16 activation domain (AD) (Figure 3B).The GAL4-VP16 synthetic transcription factor is driven by
the Mitochondrial Ribosomal Protein 7 (MRP7) constitu-
tive promoter, resulting in very low background levels of
reporter gene expression. Activities of GAL4-DBD:START:
VP16-AD (GSV) synthetic transcription factors were mon-
itored by their ability to activate the LacZ reporter
(Figure 3C). The yeast strain harbored an erg6 mutation to
facilitate permeability and uptake of small molecules. In a
GAL4-DBD:hER:VP16-AD (GEV) construct in which the
human estrogen receptor steroid binding domain (hER) is
placed between GAL4-DBD and VP16-AD domains, the
level of reporter activity, quantified in β-galactosidase (β-
Gal) units, was reduced to very low levels. However, these
levels were increased approximately 25-fold by the
addition of estradiol (Figure 3D), consistent with a previ-
ous report demonstrating that hER is responsive to its
biological ligand estradiol when expressed in a GEV tran-
scription factor in yeast [27]. A GAL4 DNA binding do-
main:VP16 activation domain (GV) control construct in
which the GAL4-DBD was fused directly to VP16-AD
was tested and shown to display an approximately
sixfold lower level of activity (Figure 3D).
START domains from mammalian proteins stimulate
transcription factor activity in yeast
We studied the function of the START domain in the syn-
thetic transcription factor with a mammalian StAR protein
that is known to bind cholesterol. When the START do-
main from mouse StAR was placed between the GAL4-
DBD and VP16-AD domains, we observed significantly
elevated levels of β-Gal activity in the GSV plasmid in
comparison to control plasmids, such as GV without the
START domain (approximately threefold and approxi-
mately sixfold increases; Figure 3D,E), and GEV-expressing
yeast in the absence of estradiol (approximately 10- and
approximately 20-fold increases; Figure 3D,E).
To examine the generality of this ability to stimulate tran-
scription factor function, we tested the START domains
from two other mammalian proteins, human metastatic
lymph node 64 (MLN64/STARD3) and human PCTP.
MLN64 is closely related to StAR and has been shown to
bind cholesterol [28], while the more distantly related
PCTP binds PtCho [14]. Both MLN64 and PCTP behaved
similarly to StAR in the ability to stimulate transcription
factor activity in the yeast assay (Figure 3E).
START domains from several Arabidopsis proteins also
boost transcription factor activity
Based on amino acid similarity to the mammalian coun-
terparts, the Arabidopsis genome encodes 21 HD-Zip
transcription factors that contain START domains out of
a total of 35 START domain-containing proteins [7].
Then 25 START domains from Arabidopsis were tested
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Figure 3 (See legend on next page.)
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Figure 3 The START domain stimulates transcription factor activity in yeast. (A) Mammalian StAR and a plant-derived HD-Zip transcription
factor. (B) GSV synthetic transcription factor. (C) GAL4-DBD binding to UAS from GAL10 drives a LacZ reporter. (D) The START domain stimulates
activity of the GV transcription factor. A representative experiment is shown for the START domain derived from mouse StAR. When hER is placed
between GAL4-DBD and VP16-AD (GEV), treatment with estradiol (10 μg/ml) leads to increased LacZ activity. START domain activity is unchanged by
estradiol treatment. START domain missense mutation (StARD182L) (yellow star) results in loss of activity. Removal of VP16-AD similarly results in loss of
activity, and GV that lacks the START domain results in a low level of activity. (E) Three Mammalian START domains (red) and at several Arabidopsis
START domains (green) exhibit significant activity levels in comparison to one or more controls: GV (yellow), GEV (grey) and the vector control (pRS314)
(grey). (F) The START domain is not a transcriptional AD. Removal of VP16-AD resulted in GS constructs that lack activity. (G) Over-expression of SUT1
results in elevated activity. START domains from mouse StAR or Arabidopsis ATML1 exhibit an increase in GSV activity when co-expressed with the
pSUT1 (blue). Asterisks indicate a significant difference over control plasmid (two-tailed t-test, P < 0.0005). Other constructs that do not contain a
functional START domain, i.e. StARD182L, GEV and GV, do not display increased activity. In all graphs, error bars indicate standard deviations for two
independent transformants in four trials. AD, activation domain; ATML1, Arabidopsis thaliana Meristem Layer 1; DBD, DNA binding domain; GEV, Gal4
DNA binding domain:estrogen receptor: VP16 activation domain; GSV, Gal4 DNA binding domain: START domain: VP16 activation domain; GV, GAL4
DNA binding domain: VP16 activation domain; HD, homeodomain; hER, human estrogen receptor; LacZ, gene for β-galactosidase; MRP7, Mitochondrial
Ribosomal Protein 7; SAD, START adjacent domain; StAR, steroidogenic acute regulatory protein; START, StAR-related lipid transfer; SUT1, Sterol Uptake
1; Zip, leucine zipper; ZLZ, Zip-Loop-Zipper (a plant-specific leucine zipper); β-Gal, β-galactosidase.
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MLN64 and PCTP (Figure 3E). Although the majority of
the Arabidopsis START domains assayed resulted in little
or no reporter activity, a group of five START domains
conferred enhanced transcription factor activity similar to
that of the three mammalian proteins tested.
The START domains from class IV HD-Zip transcription
factors ATML1 and PDF2 exhibited similar levels of activity
(4.4- and 3.1-fold over GV control, and 25- and 17-fold
over vector control, respectively; Figure 3E). These proteins
display a high degree of sequence conservation (90% and
95% amino acid identity and similarity, respectively) and
have been shown to be functionally redundant in vivo [20].
Similarly, At5g07260, a HD-Zip-related protein of un-
known function that lacks the HD domain, exhibited activ-
ity. In addition, two PCTP-like proteins, At4g14500 and
At3g13062, displayed weak activities that were not signifi-
cantly different from the GV control but were increased
over other plant-derived START domains (Figure 3E).
START domains do not behave as classical activation
domains
One possible explanation for the increased transcription
factor activity conferred by the START domain is that it
acts as a classical transcriptional AD. We examined
whether the START domain functions as an AD in com-
bination with GAL4-DBD by deletion of VP16-AD from
several GSV constructs. The resulting GAL4-DBD:START
(GS) constructs containing mammalian START domains
from StAR, MLN64, PCTP or Arabidopsis GL2, exhibited a
lack of reporter activity in the yeast assay, comparable to
that of the empty vector pRS314, about tenfold lower than
that of the GV control (Figure 3C,F). Consistent with these
data, when the START domain from Arabidopsis PDF2 or
GL2 was expressed as a bait in a yeast two-hybrid assay,
there was no auto-activation of reporter genes although ex-
pression of the myc-tagged GS proteins were detected by
Western blot (AK and KS, in preparation). We concludethat the START domain is not a transcriptional activator in
the classical sense, since it was found to boost the activity
of the transcription factor only when VP16-AD was also
present.
Over-expression of a positive regulator of sterol
biosynthesis increases reporter activity of GSV constructs
containing active START domains
One possible interpretation to explain the effect of the
START domain on the synthetic transcription factor is that
endogenous levels of lipid/sterol metabolites in yeast act as
ligands to regulate levels of activity. Over-expression of the
yeast transcriptional regulator Sterol Uptake 1 (SUT1) gene
elevates sterol biosynthesis activity [29]. High levels of
SUT1 likely results not only in an increase in sterols, but
may also alter the expression profiles of other lipid metabo-
lites needed for membrane synthesis. We found that co-
expression of this multi-copy plasmid carrying the SUT1
gene under control of the strong PMA1 promoter results in
increased activity of the LacZ reporter (approximately 2- to
12-fold) in GSV-expressing yeast (Figure 3G). The reporter
activity is only increased for those constructs that contain a
‘functional’ START domain that exhibits activity in yeast,
since constructs containing mutations in the START do-
main do not yield significant levels of transcriptional
activity (see below). These data suggest that SUT1 over-
expression acts directly or indirectly on START domains
within the GSV constructs.
Over-expression of the SUT1 gene has also been shown
to enhance sterol uptake [29]. However, exogenous addition
of cholesterol to the medium did not increase the activ-
ity of the LacZ reporter in SUT1 over-expressing cells
with GSV constructs containing the START domain
from StAR (Additional file 1: Figure S2). With SUT1
over-expressed, the reporter activity for GSV-StAR did
not change with a range of cholesterol concentrations
from 0 μM to 50 μM, perhaps due to saturation of
ligand-binding.
Figure 4 (See legend on next page.)
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Figure 4 Mutational analysis of amino acids required for StAR START domain activity in yeast assay. (A) Structural alignment of START
domains from MLN64, StAR, STARD4 and PCTP with MLN64 as a reference. Consensus α-helices and β-sheets are displayed with ESPript/ENDscript.
Amino acids targeted for site-directed mutagenesis of StAR START are indicated in yellow. Ligand contact points (green), as derived from the
PCTP-PtCho co-crystal [14], are shown for PCTP. (B) Site-directed mutagenesis of the START domain from mammalian StAR. Activities are indicated
for GSV constructs that contain missense mutations in the START domain. The M143R;N147D and R181L mutants display wild-type and slightly
elevated activities, respectively. L270M renders partial activity, while the other five mutants exhibit low or no activity. Uninduced GEV served as
the control. Error bars indicate standard deviations for two independent transformants in four trials. (C-F) Trichomes are shown from second
leaves of Arabidopsis seedlings. Scale bar: 100 μm. (C) Wild-type (WT), (D) gl2 mutant and gl2 lines transformed with (E) ProGL2:EYFP:GL2-StAR-START
and (F) ProGL2:EYFP:GL2-StAR-D182L-START, in which the START domain of StAR contains the D182L missense mutation. Live imaging of leaf
trichomes indicates nuclear localization of (H) EYFP:GL2-StAR-START and (J) EYFP:GL2-StAR-D182L-START (white arrows). (G, I) Light (green,
chlorophyll) and (H, J) matching fluorescence (red, chlorophyll). Scale bar: 100 μm. (K) Quantification of trichomes on first leaves. Error
bars indicate standard deviations for n = 20. The asterisk marks a significant difference between EYFP:GL2-StAR-START and EYFP:GL2-StAR-D182L-START
(two-tailed t-test, P < 0.00001). EYFP, enhanced yellow fluorescent protein; GEV, Gal4 DNA binding domain:estrogen receptor:VP16 activation domain;
GL2, Glabra2; MLN64, Metastatic Lymph Node 64; PCTP, phosphatidylcholine transfer protein; PtCho, phosphatidylcholine; StAR, steroidogenic acute
regulatory protein; START, StAR-related lipid transfer; WT, wild type.
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for ligand-binding
Functional analysis of specific amino acids within the
START domain of the mammalian StAR protein was car-
ried out to test further the idea that the START domain
is a ligand-binding module within the GSV transcrip-
tion factor. Using site-directed mutagenesis, missense mu-
tants were constructed on the basis of conservation and
alignment with known binding sites in PCTP (Figure 4A).
Among the eight mutants tested, two were double mutants.
The M143R;N147D double mutant has two amino acids
altered that are conserved among the mammalian
cholesterol-binding START domains. Altering the M/N
pair to R/D is predicted to change the specificity of the
StAR START domain from cholesterol-binding to zwitter-
ion lipid-binding, making it more similar to that of PCTP
[16]. Similarly, the L270M mutant is predicted to alter lig-
and specificity from cholesterol-binding to phospholipid-
binding. The other missense mutants remove or create
additional charged residues within the hydrophobic
ligand-binding cavity. The L241R mutation disrupts a
hydrophobic cluster within a PCTP binding region in the
11th β-sheet (β11) of the predicted structure. Likewise,
the F266L mutation affects the charge of a residue that is
both highly conserved and is a predicted ligand contact
site. R181L, a mutation that corresponds to a substitution
in human patients exhibiting lipoid CAH, affects the
charge of a highly-conserved residue within β6 of the
START domain that contains other residues implicated in
direct ligand contact. In the R181L;D182L double mutant
affecting the same region, two adjacent charged residues
are changed to leucines. C223R, like R181L and D182L,
affects the charge of the cavity, although this residue is
also not predicted to be in direct contact with the ligand
[14]. However, an adjacent residue, Met at position 224, is
mutated (M224T) in a subset of lipoid CAH patients [16].
The activities of the mutants were compared to wild-
type StAR (Figure 4B). Although most of the mutations in
StAR reduce or completely abolish function, the R181Lmutant, which is predicted to affect lipid transfer but not
binding [30], displayed wild-type levels of activity. The
two mutants, L270M and M143R;N147D, that were pre-
dicted to affect specificity, resulted in wild-type and partial
activities, respectively.
To examine whether a mutant version of the StAR
START domain affects transcription factor activity of
the HD-Zip GL2 protein in planta, a ProGL2:EYFP:GL2-
StAR-START transgene harboring the D182L missense
mutation was constructed and transgenic lines were ana-
lyzed in comparison to the wild-type counterpart. Among
several independent lines for which expression of the
transgene was verified, fewer branched trichomes were
observed compared to a GL2 transgene containing the
wild-type StAR-START domain (Figure 4C–F; Additional
file 1: Figure S3). Nuclear localization of the EYFP:GL2-
StAR-D182L-START transcription factor indicated that
the mutant protein is expressed and properly localized
(Figure 4G–J). Quantification of trichomes on first leaves
revealed significantly reduced function for the GL2-StAR
protein containing the D182L mutation compared to the
wild-type version (Figure 4K). These results indicate that a
functional ligand-binding START domain is required for
GL2 transcription factor activity.
Protein levels of GSV transcription factors and the
relation with activity levels
One possibility for explaining the ability of the START
domain to stimulate transcription factor activity is that it
may stabilize protein levels when it is ligand-bound. We
utilized the yeast system to further probe the mechanism
by which the START domain functions to enhance tran-
scription factor activity, by examining protein levels for a
representative subset of the GSV synthetic transcription
factors. Because we were not successful in detecting the
GSV proteins with commercial antibodies against GAL4
or VP16, likely due to very low expression levels from the
MRP7 promoter, the GSV transcription factors were fused
to the yeast-enhanced green fluorescent protein (yEGFP3)
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Green fluorescent protein (GFP) expression levels were
quantified by flow cytometry (Additional file 1: Figure
S4B,C). Each of the GSV:yEGFP3 constructs exhibited a
GFP level above the negative control (Additional file 1:
Figure S4B), and the mean values of fluorescent signals
were similar to each other (mean range: 36 to 49) in con-
trast to that of the control (mean: 12) (Additional file
1: Figure S4C). These data indicate that each of the GSV:
yEGFP fusion proteins is properly expressed in yeast.
We assayed the GSV-yEGFP3 constructs for reporter
gene activity in the yeast assay (Additional file 1: Figure
S4D). Levels of expression, as monitored by percentage
GFP, do not strictly correlate with transcription factor
activity levels, since START domains that lacked activity
(StARC223R and StARF266L) displayed similar percentage
GFP levels (0.12 and 0.10) as START domains that dis-
played activity (ATML1 and PDF2) (0.11). However, the
three GSV:yEYFP3 constructs that displayed the lowest
percentage (0.03) of GFP cells (Arabidopsis GL2, mouse
StARD182L and StARL241R), also displayed low levels of
transcription factor activity. These results suggest that
the ligand-binding activity of a given START domain
may result in increased protein stability.
Identification of metabolites bound to START domains in
the yeast system
To investigate the molecular nature of the ligands under-
lying activation of the GSV transcription factors, we used
a modified version of a metabolite–protein isolation
protocol that was developed for yeast proteins [32]. For
these experiments, we chose a subset of GSV transcription
factors carrying START domains from mouse StAR, hu-
man PCTP, Arabidopsis HD-Zip transcription factors
PDF2 and GL2, as well as an Arabidopsis PCTP-like pro-
tein At3g13062, and tagged these GSV proteins with an
immunoglobulin G (IgG)-binding domain [33] (Figure 5A).
As negative controls, we included the D182L mutant ver-
sion of the START domain from mouse StAR that exhibits
reduced activity in both yeast and plants (Figure 4) and
the GV fusion that lacks the START domain altogether.
Small metabolites bound to the tagged proteins were
identified by affinity protein purification followed by mass
spectrometry. We focused on the metabolites significantly
enriched in the GSV transcription factors relative to the
GV control. A shortlist of candidate masses were queried
against the Human Metabolome Database (HMDB) and
METLIN to identify and assign a metabolite name to the
enriched features at a high or low confidence level
(Additional file 2: Table S1). Purified proteins correspond-
ing to each sample were examined by SDS-PAGE, which
indicated expression of GSV-IgG (and GV-IgG control)
proteins of expected sizes (Figure 5B). In parallel, the GSV-
IgG constructs were tested for activity in the yeast assay(Figure 5C), and shown to behave in a similar manner as
the original GSV constructs (Figures 3E and 4B). While
GSV transcription factors containing START domains from
mammalian StAR and PCTP, as well as Arabidopsis PDF2
and At3g13062 displayed activity levels that were increased
over the GV control, the START domains from the
StARD182L mutant and Arabidopsis GL2 displayed low
levels of activity.
Hierarchical clustering of the mass spectrometry data
revealed several distinct clusters of protein–metabolite
interactions (Figure 5D). The horizontal dendrogram
places the GSV-StAR transcription factor in a separate
cluster from the missense mutant StARD182L. The
enriched metabolites of StARD182L, which clustered with
the Arabidopsis At3g13062 START domain, are distin-
guished by an abundance of several distinct species of
diacylglycerols. The remaining proteins are grouped by
the horizontal clustering dendrogram such that both
Arabidopsis PDF2 and GL2 START domains have more
similar bound-metabolite preferences, with human PCTP
being more closely related to this group than the mouse
StAR domain. In addition to several metabolites that were
shared with StAR (e.g. lanosterol, squalene, PtCho, diacyl-
glycerol and LysoPtCho), PCTP was shown to bind repro-
ducibly to several types of lipids including sphinganine,
sphingosine, behenic acid and linoleamide. The vertical
dendrogram reveals a major metabolite cluster comprising
StAR, PCTP, PDF2 and GL2 that contains an overrepre-
sentation of LysoPtCho. Metabolites common to PCTP,
StAR and the mutant StARD182L form a distinct cluster,
which includes some phospholipids, such as PtCho and
LysoPtCho, as well as several sterols including four chol-
esterol esters (CEs). This cluster also includes two major
precursors of the cholesterol biosynthesis pathway, lanos-
terol and squalene. The mutant StARD182L is significantly
less enriched for CE, PtCho, LysoPtCho, squalene and
lanosterol within this cluster.
Additional file 2: Table S1 provides a detailed list of
significant features that were enriched or depleted for
individual GSV transcription factors. Although the over-
all chemical nature of the bound metabolites are diverse
in class, glycerolipids and phospholipids together com-
prise the majority of interacting metabolites identified.
We generated a comprehensive protein–metabolite net-
work (Additional file 1: Figure S5A) from enrichment
data in Additional file 2: Table S1 for all six START
domains tested. To compare and contrast metabolite
binding preferences better, we constructed sub-networks
(Additional file 1: Figure S5B,C and Figure 6A) from a
more stringent filtering, and included only high confi-
dence and validated metabolites. The data support a
hypothesis that the START domains from plant and
mammalian origin can interact with a common set of



















































































































































































































Figure 5 (See legend on next page.)
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Figure 5 Expression and activity of tagged GSV transcription factors and dendrogram from protein–metabolite immunoisolation.
(A) GSV translational fusion to a triple tag (6x-HIS (white), HA-epitope (dark blue), Protease 3C cleavage site (orange), and IgG binding domain ZZ
(yellow)) in pBG1805 [33]. (B) Immunoisolation of tagged proteins with IgG Sepharose beads followed by SDS-PAGE. One of four biological
replicates is shown. Y258 URA3+ (lane 1) served as the negative control, while GSV proteins are indicated by red asterisks. The GV fusion lacking
the START domain is marked by a black asterisk. Arrowheads indicate IgG heavy and light chains. (C) Tagged GSV constructs were expressed in
erg6 cells containing the LacZ reporter and transcriptional activity was measured in β-Gal units. Double asterisks indicate a significant increase in
activity over the GV control (two-tailed t-test, P < 0.03). Error bars indicate standard deviations for two independent transformants in four trials.
(D) Dendrogram from protein–metabolite immunoisolation. Two-way hierarchical clustering was performed on the metabolite enrichment data
relative to the GV control with values expressed as the logarithm base 2 (ratio) of normalized metabolite intensities. Horizontal clusters represent
START domain clusters based on protein-bound metabolite enrichment. Vertical clusters show groups of protein-bound metabolites clustered by
START domain. Metabolite names marked by asterisks were validated by mass spectrometry, matching exact mass and retention time to a known
standard. CE Metabolites of the same chemical subclass were grouped and given a superscript number to distinguish members that bear distinct
masses and retention times. aa, amino acids; AD, activation domain; DBD, DNA binding domain; GL2, Glabra2; GSV, Gal4 DNA binding domain:START
domain:VP16 activation domain; GV, GAL4 DNA binding domain:VP16 activation domain; IgG, immunoglobulin G; PCTP, phosphatidylcholine transfer
protein; PDF2, Protodermal Factor 2; StAR, steroidogenic acute regulatory protein; START, StAR-related lipid transfer.
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ligand-binding cavities
From their X-ray crystal structures, the ligand-binding cav-
ity volumes of mammalian START domains from MLN64
(848 ± 107 Å3) [16] and PCTP (approximately 882 Å3) [14]
are highly similar although they bind different hydrophobic
ligands. Cholesterol, the ligand of MLN64, occupies a
741 Å3 volume, while PtCho, the ligand of PCTP, occupies
797 Å3. Based on our domain swap experiments in Arabi-
dopsis (Figures 1 and 2) and GSV transcription factor ac-
tivities in the yeast assay (Figure 3E), and binding activities
in the protein–metabolite immunoisolations (Figure 5),
Arabidopsis START domains from class IV HD-Zip tran-
scription factors are predicted to exhibit similar ligand-
binding cavities as their mammalian counterparts.
Using available three-dimensional coordinates for crystal
structures of mammalian START domains and threading-
based fold prediction, the closest structural homolog for
each of the Arabidopsis START domains tested in the
yeast assay was determined to be the mouse STARD4 do-
main (Figure 7A). Three-dimensional homology models
were constructed and the corresponding hydrophobic
tunnels were assessed for size, volume and identities of
the cavity lining residues. The modeling results indicated
that the hydrophobic tunnels of the Arabidopsis START
domains fall into three categories of volume sizes. Plant
START cavities were found to be either small in size
(Figure 7B; volumes less than 400 A3), medium (Figure 7C;
volumes between 400 and 700 Å3) or large (Figure 7D;
volumes >700 Å3). The five START domains showing ac-
tivity in the yeast assay fall into the large volume category.
For example, START domains from HD-Zip transcription
factors ATML1 and PDF2, which exhibit activity in the
yeast assay, have predicted volumes of 770 and 720 Å3, re-
spectively. In contrast, START domains from other HD-
Zip transcription factors, such as GL2 and Corona (CAN),
which had little or no activity in the yeast assay, fall into
the small volume category with tunnels of 284 Å3 and
320 Å3, respectively. Among the plant START domainsthat exhibited a negative result, three others are predicted
to have similarly small cavities.
Detailed examination of the predicted cavity-lining
amino acid residues in each of these cases revealed that
certain side-chain residues are oriented into the space
within the original tunnel, thereby blocking the passage
and restricting the cavity size (Figure 7E). Some frequent
blocking positions correspond to N147, A178 and G200
(StAR numbering), all of which are replaced by residues
with much larger side chains in Arabidopsis START do-
mains, such as Arg, Trp/Tyr/Phe/Gln/Asn and Ile/Leu,
respectively. Most of the domains that lack activity in
the yeast assay correspond to volumes that fall into the
medium category, while two domains from HD-Zip tran-
scription factors (HDG2 and FWA/HDG6) have cavities
of the large volume category. In the START domain
from HDG2, the opening of the tunnel is slightly shifted,
such that a potential ligand would be predicted to en-
counter steric hindrance in entering the hydrophobic
tunnel. Thus, steric factors may explain why some of the
plant-derived START domains fail to exhibit activity in
the yeast assay.
Discussion
A role for the START domain in the regulation of
transcription
Here we chose GL2, a representative family member from
Arabidopsis, to investigate the significance of the START
domain in HD-Zip transcription factors. Our results in-
dicate that the START domain is required for tran-
scription factor activity (Figures 1 and 2). Strikingly, the
GL2 START domain could be functionally replaced by the
mouse StAR START domain, a mammalian counterpart.
The GL2 START domain could similarly be replaced by
the START domain from ATML1, a transcription factor
from the same class IV HD-Zip subfamily that shares a
relatively high degree of amino acid similarity, but other
Arabidopsis START domains of lower similarity (EDR2
and REV; Figure 1F) could not functionally replace the
SAD
A
Figure 6 Protein–metabolite interaction network of mammalian and Arabidopsis START domains. (A) Cytoscape was used to visualize the
normalized protein–metabolite enrichment data in an edge-weighted interaction network where metabolite interactions held in common by the
Arabidopsis START domains were grouped to produce a single node labeled ‘Plant’, and common interactions for mouse and human proteins
(StAR, StARD182L* and PCTP) were grouped to produce a ‘Mammal’ node. Distances between protein and metabolite nodes reflect the interaction
strengths based on the magnitude of the fold-change; the shorter the edge the more enriched the metabolite. The network was filtered for
interactions with a greater than tenfold change in enrichment relative to the GV control and only high confidence metabolite assignments were
included. If a node had multiple interactions with the same chemical sub-class of metabolite (e.g. PtCho) these interactions were combined and
weighted to give one interaction. Asterisks designate metabolites that were validated by mass spectrometry, matching exact mass and retention
time to a known standard. (B) Schematic illustrating how START domains may modulate transcription factor activity in plants and mammals. In
plants, the START domain is found in HD-Zip transcription factors that contain an HD DNA binding domain. In mammals, the START domain and
the DNA binding domains are in two separate proteins. A physical interaction between the START protein PCTP and Pax3 transcription factor
comprising both paired box (PAX) and HD DNA binding domains was been reported [34]. GV, GAL4 DNA binding domain:VP16 activation domain;
HD, homeodomain; PCTP, phosphatidylcholine transfer protein; PtCho, phosphatidylcholine; SAD, START adjacent domain; StAR, steroidogenic
acute regulatory protein; START, StAR-related lipid transfer; Zip, leucine zipper; ZLZ, Zip-Loop-Zipper (a plant-specific leucine zipper).
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or structural feature is critical.
The ability of the mouse StAR START domain to confer
partial complementation may reflect the presence of the
appropriate ligand (i.e. cholesterol) in GL2-expressing cells,
whereas the ligands of EDR2 or REV START, which are un-
known to date, are potentially not present in these cells.
The conclusion that the mouse StAR START domain par-
ticipates in ligand-binding in plant cells is further supported
by our finding that the D182L mutation results in reduced
GL2 activity (Figure 4). Alternatively, there is a function un-
related to ligand-binding that the START domains of StAR
and ATML1 can fulfill. Although our structural modeling
data suggest different cavity volumes for StAR and GL2 (as
well as ATML1 and GL2), the protein–metabolite immu-
noisolation data from yeast indicate an overlap in binding
partners between GL2 and StAR, as well as between GL2
and PDF2, the closest relative of ATML1. It is noteworthythat the EDR2 and REV START domain swaps are
expressed but are not localized in nuclei (Figure 2H,I). One
possible explanation is that these START domains yield im-
properly folded transcription factors, which interfere with
transport to the nucleus. However, since the GL2 protein
lacking the START domain is found in the nucleus,
we conclude that the START domain is not strictly
required for correct subcellular localization.
START domains stimulate transcription factor activity via
ligand-binding
It was hypothesized that HD-Zip transcription factors from
plants are regulated via lipid/sterol ligands that bind to
their START domains [1,7]. The yeast assay described here
tests the function and ligand-binding properties of START
domains within a synthetic transcription factor, and indi-
cates that START domains of mammalian or plant origin






Figure 7 Comparative structural modeling of plant START domains. Ribbon diagrams of three-dimensional models comprised β-sheets
(yellow), α-helices (red) and loops (green), showing three categories of cavity volume. The hydrophobic tunnels are represented as a white mesh.
(A) Crystal structure of the mammalian START domain from STARD4. (B, C, D) Examples of small, medium and large cavity volumes, respectively,
from modeled Arabidopsis START domains. (E) Superimposition of cavities from a mammalian domain (red mesh) and a model of an Arabidopsis
domain (green mesh) to illustrate the amino acid residues that are predicted to change the dimensions of the cavity by blockage or expansion in
several plant START domains. A Trp residue (green, marked ‘block’) in the plant structure corresponding to M224 (StAR numbering) results in
shortening of the cavity length. In contrast, the mammalian cavity is restricted by W187 (red, marked ‘expand’), which corresponds to a smaller
Val residue in the plant START domain, resulting in an increase in width at the center of the cavity.
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sence of VP16 (Figure 3F), and based on our site-directed
mutagenesis, protein–metabolite immunoisolation experi-
ments and structural modeling, we conclude that the likely
mode of action is via ligand-binding. Since several START
domain-containing proteins from humans have been found
in the nucleus [8,9], our findings support a possible role
for the START domain in regulating gene expression in
both plants and animals.
Relevant to our results, mammalian PCTP was previ-
ously shown to interact physically with HD transcriptionfactor Pax3 and the two proteins are co-localized in the
nuclei of mouse embryos [34] (Figure 6B). The previous
study showed that PCTP co-activated the transcriptional
activity of Pax3 in tissue culture cells, and it was postu-
lated that the physical interaction of PCTP with Pax3
positively regulates its transcriptional activity. Perhaps
the interaction between PCTP and Pax3 is analogous to
the function of the START domain in plant HD-Zip
transcription factors (Figure 6B). While the previous
study examined the function of the START domain in
an interacting protein [34], here we demonstrate the
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of the transcription factor.
We probed three mammalian START domains and
25 Arabidopsis START domains for the ability to stimu-
late transcription factor activity in yeast (Figure 3E).
While all three mammalian START domains exhibited
activity in comparison to the control, only 5/25 of the
Arabidopsis START domains displayed similar levels of
activity. Using protein–metabolite immunoisolation experi-
ments (Additional file 2: Table S1, Figures 5 and 6, and
Additional file 1: Figure S5), we tested the idea that lipids/
sterols present in yeast bind the corresponding START
domains, resulting in the observed activity. We reasoned
that START domains that lack activity might require plant-
specific metabolites not found in yeast. The Arabidopsis
GL2-START domain, which displays little or no activity in
yeast, was found to bind to a large number of metabolites.
The range of metabolites bound to the START domains
from Arabidopsis PDF2 (showing activity) and GL2 (lacking
activity) were overlapping but not identical, leaving the pos-
sibility that those specific to GL2 might behave as negative
regulators. In general, protein–metabolite interactions may
serve to: (a) activate or negatively regulate proteins, (b)
stabilize protein levels, and/or (c) facilitate protein–protein
interactions [35]. In addition to activating or negatively
regulating transcription factor function, our experiments
with the yEGFP3 fusions provide evidence that ligand-
binding stabilizes protein levels of the GSV transcription
factors (Additional file 1: Figure S4). In addition, ligand-
binding may also contribute to correct protein folding.
Site-directed mutagenesis of the START domain from
mouse StAR was utilized in conjunction with the yeast
assay to characterize START domain function further
within the synthetic transcription factor. Our results indi-
cate that transcription factor activity correlates with pre-
dicted ligand-binding capacity of the START domain
(Figure 4). From the protein–metabolite immunoisolation
experiments, comparison of the wild-type START domain
from StAR versus the mutant StARD182L reveals that many
more metabolites (including CEs) bind to the wild-type
StAR, correlating high levels of activity with ligand-binding
in the yeast assay. Consistent with the interpretation that
our yeast assay measures ligand-binding, the StARR181L
mutation, which displays wild-type levels of activity, was
reported not to affect ligand-binding affinity in vitro [36].
In transfected mammalian cells, this missense mutation has
an adverse effect on cholesterol transfer and the corre-
sponding conserved Arg may be required for a conform-
ational change that allows release of bound ligand. The
StAR mutants that are predicted to change the specifi-
city of ligand-binding had little (StARL270D) or no affect
(StARM143R;N147D) on the activity of the START domain
in the yeast assay. This finding was consistent with the
results from our protein–metabolite immunoisolationexperiments, in which a range of lipid metabolites includ-
ing PtCho and sterol-related molecules were found associ-
ated with the tagged GSV transcription factor containing
the START domain from StAR (Additional file 2: Table S1
and Figures 5 and 6A). We propose that interaction of
START domains with accessory proteins, via tissue-specific
expression and proper subcellular compartmentalization,
are likely to contribute to specificity in binding of selected
metabolite ligands during the lifespan of the protein within
the cells of the host organism.
Immunoisolation experiments reveal novel
protein–metabolite interactions for START domains
The GSV protein–metabolite immunoisolation experi-
ments performed in yeast uncovered potential lipid ligands
for mammalian StAR and PCTP that had previously been
shown to bind these START domains, namely cholesterol
(eg. CE) and PtCho, respectively (Additional file 2: Table
S1, Figure 5 and Additional file 1: Figure S5). In addition,
novel metabolite–protein associations were found, in-
cluding known modulators of lipids and sterols in mam-
mals, such as sphinganine, behenic acid and LysoPtCho.
Precursors and intermediates of the sterol biosyn-
thesis pathway, including lanosterol and squalene, were
also significantly enriched for the START domain from
StAR.
There is mounting evidence for a broad range of potential
binding partners for a given START domain. In a previous
study, it was shown that StAR can stimulate the transfer of
both cholesterol and β-sitosterol, a plant sterol, from lipo-
somes to mitochondria [37]. A structural study showed that
in addition to ceramides, the START family member cer-
amide transfer protein (CERT) binds diacylglycerol [17], an-
other metabolite that was uncovered here. It is noteworthy
that key lipid metabolites in low-density lipoprotein (LDL)
transport, namely CE and LysoPtCho, which are converted
from cholesterol and PtCho by lecithin-cholesterol acyl
transferase (LCAT), an enzymatic reaction that is critical
for LDL transport in the cell, were found to be associated
with several START domains that we tested. The identified
START domain interactor sphinganine is a known choles-
terol transport inhibitor that blocks LDL-induced forma-
tion of CE, the product of LCAT activity [38]. Behenic
acid, which was found enriched only in PCTP and not the
other START domains, has been reported to increase chol-
esterol levels in humans [39]. Taken together, our findings
support the premise that START domains are central
players in metabolic regulatory networks in the cell.
Conclusions
The START domain has been characterized primarily as
a lipid/sterol-binding domain in mammals, but its func-
tion in plant HD-Zip transcription factors was previously
not known. Here we show that the START domain is
Schrick et al. BMC Biology 2014, 12:70 Page 16 of 20
http://www.biomedcentral.com/1741-7007/12/70required for transcription factor activity of GL2, a represen-
tative member of the family of class IV HD-Zip transcrip-
tion factors in plants. We report evidence that START
domains from the plant kingdom can act as ligand-binding
modules, similar to their mammalian counterparts, and
that they can modulate transcription factor activity. The
protein–metabolite immunoisolation experiments per-
formed in yeast generated a list of small molecules that
are candidates for binding the Arabidopsis START do-
mains from HD-Zip transcription factors within the
physiological context of plant growth and development. In
addition, the unexpected protein–metabolite interactions
that were detected for the two mammalian START do-
mains tested, StAR and PCTP, may represent additional
small molecule binding partners that regulate these
START domains in human cells. In summary, the results
presented here provide new insights into the molecular
mechanisms underlying START domain function in
eukaryotic cells, and reveal novel protein–metabolite in-
teractions that may play critical roles in modulating tran-
scription factor activity in both animals and plants.
Methods
Plants, growth conditions, plant constructs and
phenotypic assays
The wild-type Arabidopsis thaliana ecotype used was
Columbia (Col). The gl2 null allele was gl2-5 [40]. Seeds
were stratified at 4°C for 3 to 5 days and grown on soil mix
containing Supersoil (McLellan Co, Marysville, OH), ver-
miculite and perlite (McConkey Co, Sumner, WA) in 4:3:2
ratio at 23°C under continuous light. The GL2 cDNA was
sub-cloned into pBluescript via KpnI and SalI restriction
sites to serve as a template for the deletion construct.
Phusion® Site-Directed Mutagenesis Kit (Thermo Fisher
Scientific, Waltham, MA) was used to generate the START
domain deletion, following the manufacturer’s protocol.
After sequence confirmation, the GL2 START deletion
cassette was restriction digested with KpnI and SalI, and
ligated into the binary vector SR54 (ProGL2:EYFP:GL2),
which is derived from pCAMBIA1300. Construction of
ProGL2:EYFP:GL2 will be described elsewhere (AK et al.,
manuscript in preparation). For domain swap constructs,
the START domain sequences were amplified using PCR
from corresponding cDNA clones using Phusion
High-Fidelity DNA polymerase (Thermo Fisher Scientific,
Waltham, MA). The REV sequence contained mutations in
the microRNA binding site as in [41]. Gene-specific
primers with 15-bp extensions homologous to vector
ends were used to amplify the insert followed by In-
Fusion HD cloning reactions (Clontech, Mountain
View, CA) using a PCR-amplified pBluescript plasmid
harboring the GL2 cDNA with flanking homologous
ends. For the mutant version of GL2-StAR-START,
site-directed mutagenesis was performed as describedbelow for the yeast constructs. The reconstructed GL2
cDNAs were cloned into the SalI/KpnI sites of binary
vector SR54 carrying ProGL2:EYFP:gl2-STARTΔ. The
constructs were transformed into gl2-5 plants by floral
dip transformation using Agrobacterium strain GV3101
(pMP90) [42]. Transgenic plants were selected with
50 μg/ml hygromycin B. Segregation patterns for EYFP
expression were observed in T2 progeny of >30 inde-
pendent lines. T3 homozygous lines with stable EYFP
expression were confirmed by PCR and assayed for leaf
trichomes, root hairs and seed coat mucilage. For muci-
lage analysis, seeds were stained in a 0.25% aqueous so-
lution of ruthenium red (Sigma, St. Louis, MO) for 2 h
and replaced with deionized water prior to observation.
Seeds, rosettes and roots were imaged with a Leica M125
fluorescence stereo microscope, and images were captured
using a Leica DFC295 digital camera and Leica Appli-
cation Suite software version 4.1. Ovules were excised
from siliques, stained with 1 μg/ml DAPI (Sigma, St. Louis,
MO) and imaged with Zeiss LSM 510 meta and chameleon
modules with standard settings for visualization of yellow
fluorescent protein and DAPI fluorophores. Oligonucleo-
tide sequences used to make DNA constructs are listed in
Additional file 1: Table S2.
Yeast strains and growth media
The genotype of the Saccharomyces cerevisiae wild-type
strain was MATα leu2-3,112:: UASGAL10-lacZ-LEU2
his3Δ gal4Δ ura3-52. The genotype of erg6 mutant strain
was: MATα erg6-Δ1 leu2-3,112::UASGAL10-lacZ-LEU2
his3Δ gal4Δ ura3-52. These strains were constructed
from a cross between YGY13 [27] and CJY004 [43]. For
protein expression, Y258 (MATa pep4-3, his4-580, ura3-52,
leu2-3,112) cells were used. Y258 with an integrated URA3
gene from the pRS426 vector was a negative control for
ligand-binding studies [32]. Growth media were made
according to standard protocols. DNA constructs were in-
troduced into yeast using a standard lithium acetate trans-
formation method [44].
Yeast plasmids and DNA constructs
For each GSV construct, the START domain sequence
was amplified using PCR from the corresponding cDNA
clone or an Arabidopsis cDNA library [45] and ligated
in-frame into the KpnI/SacI restriction sites of pGEV-HIS3
[27,46]. cDNA clones of the following genes were obtained
from the RIKEN Arabidopsis full-length clones collection
[47]: HDG2 (At1g05230), ANL2 (At4g00730), HDG1
(At3g61150), HDG12 (At1g17920), HDG11 (At1g73360),
HDG8 (At3g03260), At5g07260, PHB (At2g34710),
CNA (At1g52150), ATHB-8 (At4g32880), At5g35180,
At5g45560, At2g28320, At1g64720, At5g54170, At4g14500
and At3g13062. When cDNA inserts had internal KpnI
and/or SacI sites, site-directed mutagenesis and primer
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the nucleotide sequences without altering the amino acid.
To construct GS translational fusions from GSV plasmids,
VP16-AD was removed by restriction digestion with
SacI, followed by ligation. The empty vector control was
pRS314. The GV control construct lacking the START do-
main was made using site-directed mutagenesis and pri-
mer extension PCR of the GSV-StAR plasmid to insert
NruI sites at the junctions of its START domain followed
by restriction digestion with NruI, and re-circularization.
To construct the control vector for the SUT1 over-
expression experiments, pSUT1 (pNF1) [29] was re-
striction digested with NotI to remove the SUT1 gene,
followed by ligation. To construct translational C-terminal
fusions to the yEGFP3 [31], the coding regions for the
GSV transcription factors were cloned into the pUG35
plasmid using BamHI/EcoRI restriction sites. Site-directed
mutagenesis followed by primer extension PCR was used
to insert an ATG codon in the polylinker of pUG35 5′ to
the BamHI site. For protein expression in conjunction
with the identification of in vivo ligands, the coding re-
gions for GSV transcription factors containing START do-
mains from StAR, StARR182L, PCTP, GL2, PDF2 and
At3g13062, as well as the GV control were cloned into
pENTRTM-D-TOPO® (Life Technologies, Carlsbad, CA)
and then moved into pBG1805 [33] by Gateway® LR
clonase II (Life Technologies, Carlsbad, CA). Oligonucleo-
tides used for plasmid construction, site-directed muta-
genesis and sequence confirmation are listed in Additional
file 1: Table S2.
Quantitative β-galactosidase assay
Yeast cultures were grown to exponential phase in 24-well
plates (2 ml media per well) at 30°C and 300 rpm using a
thermoshaker. OD655 measurements were taken prior to
centrifugation. Cell pellets were washed and suspended in
100 μl Z-buffer (60 mM Na2HPO4, 40 mM NaH2PO4,
10 mM KCl, 1 mMMgSO4•7H2O) followed by two freeze-
thaw cycles, and addition of 700 μl Z-buffer containing
50 μM β-mercaptoethanol. Then 160 μl ortho-Nitrophe-
nyl-beta-galactoside (4 mg/l) was added to each sample
sequentially at 15-s intervals, followed by incubation in a
1,200 rpm thermoshaker at 30°C. Samples were monitored
for the development of a yellow color, after which the re-
action was stopped by addition of 400 μl of 1 M NaCO3.
A415 measurements of the supernatants were taken and β-
Gal activity was calculated in Miller units [49].
Site-directed mutagenesis of the START domain of StAR
START domains from ATML1, PDF2, GL2, MLN64/
STARD3, StAR/STARD1 and PCTP/STARD2 were aligned
using ClustalW [50] and Jalview [51]. Site-directed muta-
genesis of mStAR-GSV was performed using a one-step
PCR-based method [48]. Reaction mixtures contained25 ng template DNA, 135 ng of each oligonucleotide, 1 μl
of 10 mM deoxynucleotide triphosphates, 1 μl PfuUltra™
High-Fidelity DNA Polymerase (Agilent Technologies,
Santa Clara, CA), 5 μl buffer supplied with the polymer-
ase, and H2O in 50 μl. PCR conditions were: 95°C de-
naturation for 1 min; 16 cycles of 95°C for 50 s, 60°C for
50 s, and 68°C for 1 min/kb; extension at 68°C for 7 min.
PCR products were digested with 30 U of DpnI for 3 h at
37°C, followed by ethanol precipitation and transform-
ation of XL10-Gold® Ultracompetent Cells (Agilent
Technologies, Santa Clara, CA).
Identification of in vivo ligands: affinity purification and
metabolite extraction
Y258 ura3-52 yeast cultures expressing pBG1805 con-
structs were grown in raffinose until they reached an
OD600 of 0.5 to 1.0. The Y258 strain with an integrated
URA3 selectable marker that was not transformed with
the tagged construct served as a minus protein control for
non-specific binding. Galactose was added to induce gene
expression for 6 to 8 h at 30°C, and cell pellets were col-
lected from 300 ml cultures. Protein expression was moni-
tored after purification from lysates with IgG Sepharose 6
(GE Healthcare, Little Chalfont, United Kingdom) using
SDS-PAGE. For the identification of protein-bound ligands,
proteins were isolated from lysates using rabbit IgG-
crosslinked M-270 epoxy Dynabeads (Life Technologies,
Carlsbad, CA) as described [32] with some modifications.
After 2 hr incubation at 4°C, the beads were washed in
500 mM NH4Ac followed by 50 mM NH4Ac for 5 min
each. Using an improved metabolite extraction method
(MB and MPS, unpublished data), Dynabeads were briefly
(1 min) incubated in 15 μl 95% methanol/5% H2O with
acetic acid added to give a final pH of 4.5, then neutralized
by 45 μl of 95% methanol/5% H2O with ammonium hy-
droxide and incubated for 8 min at room temperature. The
extract was aspirated, stored on ice, and 30 μl fresh 100%
methanol was added to the beads with incubation for
10 min at room temperature. Extracts were combined prior
to mass spectrometry. To examine protein levels, the beads
were boiled in 30 μl 2× SDS sample buffer for 10 min and
15 μl of the supernatant was analyzed by SDS-PAGE.
Mass spectrometry and data analysis
AThermo LTQ Orbitrap Velos mass spectrometer equipped
with a heated electrospray or atmospheric-pressure chemical
ionization source was used for ionization and detection of
the samples following separation using ultra performance
liquid chromatography. A phenyl column was tested with
cholesterol first and a gradient method was developed to
screen in both positive and negative ionization modes
using heated electrospray ionization with optimized pa-
rameters in a methanol/water 0.1% formic acid mobile
phase system. Extracts were additionally screened using
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pressure chemical ionization source and optimized pa-
rameters. For data analysis, raw files were converted,
peaks centroided and parameters optimized for peak iden-
tification in MZmine. The data, collected from three tech-
nical replicates in each of four biological replicates (12
data points per peak), were median normalized. A two-
tailed t-test was performed relative to the Y258 URA3
control to filter out non-essential features and noise. The
normalized data representing each sample and GV control
were aligned by mass and retention time using the SIMA
algorithm [52], and peak intensities were adjusted by nor-
malizing for different protein levels (Additional file 2:
Table S1). Any peak not present in at least 80% of all
replicates and not enriched to greater than fourfold
relative to the GV control was excluded from further
analysis. Both HMDB and METLIN databases were quer-
ied with the remaining M/Z values to identify metabolites
within a 2-ppm mass tolerance. Unknown features were
removed. Features that yielded database hits were compared
to the GV control to calculate fold-change enrichment and
to facilitate further filtering. Analysis of known chemical
standards permitted validation of metabolites identified ini-
tially by accurate mass, and of the 27 tested, all 27 matched.
Of the 109 features that were significantly enriched, 65 had
a high confidence metabolite assignment based upon query-
ing the determined mass against the HMDB and METLIN
databases (Additional file 2: Table S1). Hierarchical cluster-
ing was performed with Cluster 3.0 [53] and visualized with
Treeview [54]. Cytoscape [55] was employed to generate
protein–metabolite networks using the edge-weighted
force-directed layout based on interaction weight. The high
confidence and standard matched protein–metabolite inter-
actions were assigned the identifier EBI-9687416 and depos-
ited to the IntAct database [PMID:22121220] within the
International Molecular Exchange (IMEx) Consortium. The
IntAct dataset represents a subset of the total interaction
data with corresponding unique PubChem identifiers, as li-
quid chromatography–mass spectrometry was unable to
distinguish certain molecules, e.g. PC(20:4(5Z,8Z,11Z,14Z)/
21:0) versus PC(21:0/20:4(5Z,8Z,11Z,14Z)).
Three-dimensional structural data analysis
The closest structural homolog for each Arabidopsis
START domain was identified by fold recognition or
threading based predictions using PSIPRED [56,57] with
‘Fold Recognition’ as the prediction method [57,58]. Three-
dimensional coordinates for available crystal structures of
START domains, either unbound (mouse STARD4 (Protein
Database (PDB) 1JSS) and mouse MLN64 (PDB 1EM2)) or
ligand-bound (human PCTP (PDB 1LN1)) were obtained
from Brookhaven Protein Structure Database. To construct
atomic-resolution models of Arabidopsis START domains,
the closest structural homologs identified by threading wereused as templates for model building in alignments using
MODELLER 9v2 [59]. Structure validation for homology
models was carried out with PROCHECK [60] and WHAT
IF [61]. For the models that passed structure validation
tests, tunnel architectures were examined using VOIDOO
[62] with a probe radius of 1.4 Å. The remaining cavities
were rendered by MAPMAN [56] and visualized in PyMOL
Molecular Graphics System V.1.3 (Schrödinger, LLC, New
York, NY) on an Intel Dual Core iMAC installed with OS
X version 10.6.5 (2.4 GHz, 4 GB RAM). VOIDOO identi-
fied a large number of cavities, of which ambiguous and
false positives were filtered out by manual visualization of
cavities in the context of predicted cavity lining residues.
Additional files
Additional file 1: Additional methods, figures and tables. Additional
methods: Flow cytometry. Figure S1. Trichomes on first leaves of gl2
mutants transformed with GL2 constructs. This figure is supplemental to
Figure 1, and shows scanning electron micrographs of trichome
morphologies on first leaves of gl2 mutants, in comparison to wild-type
GL2 and GL2 in which the START domain is replaced by mouse StAR or
ATML1 START. Figure S2. Exogenously supplied cholesterol does not alter
activity levels of StAR-GSV. This figure is supplemental to Figure 3G, and
shows that the exogenous application of cholesterol to the yeast cells
does not alter activity levels of GSV-StAR. Figure S3. Rosette phenotypes
of mouse StAR START versus the D182L missense mutant expressed in
the GL2 transcription factor. This figure is supplemental to Figure 4. In
comparison to wild-type mouse StAR-START, which exhibits partial rescue
of the trichome defect of gl2, the D182L missense mutation leads to a
reduction in trichome cell differentiation on rosette leaves. Figure S4.
In vivo expression of GSV constructs as yEGFP3 fusions in yeast. This figure
is supplemental to Figures 3 and 4, and illustrates how fusions to yEGFP3
were used to examine expression levels of GSV constructs compared to
their activity levels in the yeast assay. The relevant raw flow cytometry
data are shown. Figure S5. Protein–metabolite interaction network for
mammalian and Arabidopsis START domains. This figure is supplemental
to Figures 5 and 6, and shows the protein–metabolite network for all
interaction levels with greater than fourfold change as well as two
sub-networks separately highlighting strong interactions common among
the mammalian and Arabidopsis START domains, respectively. Table S2.
Oligonucleotides used in this study. This supplemental table provides a
list of oligonucleotide primers used to make DNA constructs, to perform
site-directed mutagenesis, and to confirm DNA constructs by sequencing.
Additional file 2: Table S1. Summary table of mass spectrometry
features profiled by screening START domains for protein-bound metabolites.
This supplemental table provides the numerical mass spectrometry data used
in constructing Figures 5 and 6. It is presented in an Excel (xls) spreadsheet
because of the large size and large volume of data in the table.
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